Jump to content

Schott Pharma

Edit links
From Wikipedia, the free encyclopedia
(Redirected from Draft:Schott Pharma)
Schott Pharma AG & Co. KGaA
Company typeKGaA with Aktiengesellschaft as partner with unlimited liability
FWB: 1SXP
ISINDE000A3ENQ51
IndustryHealthcare
FoundedAugust 1, 2022; 2 years ago (2022-08-01)
HeadquartersMainz, Germany
Key people
Andreas Reisse, CEO
Almuth Steinkühler, CFO
ProductsPharmaceutical drug containment and delivery systems
Revenue€899 million (2022/2023)[1]
OwnerSchott AG
Number of employees
4,646 (as of September 30, 2023)[1]
Divisions
  • Drug Containment Solutions
  • Drug Delivery Systems
Websiteschott-pharma.com

Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2][3] Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023.[4] Headquartered in Mainz, Germany,[5][6] the company operates in 14 countries.[7]

History

[edit]
Filling Schott glass ampoules with medications (1932)
Schott & Gen. advertisement for borosilicate glass vials (1923)

In 1887, Otto Schott developed borosilicate glass, a form of glassware used to reagent bottles and flasks. From 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[8]

Schott Pharma was established as a standalone company in 2022 under the name Schott Pharma AG & Co. KGaA[9][6] through an equity carve-out (or spin-off) from Schott AG, a manufacturer of specialty glass and glass-ceramics.[10][11] In the same year, the company announced their plans to present an IPO, but this was reportedly postponed to 2023 due to the Russian invasion of Ukraine.[5]

In June 2023, Schott Pharma announced plans to hold the IPO in September 2023.[12] This plan was enacted in September, with Schott Pharma going public on the Frankfurt Stock Exchange.[13] The IPO was initially priced at 27€ per share,[14][15] and a potential valuation of up to 4.1 billion euros,[16] but increased the share price to 30€ the following day.[17][13] The IPO was the largest of the year in Germany.[18][19] In December 2023, Schott Pharma was included in the SDAX.[20] In September 2024, Schott Pharma was promoted to the MDAX.[21]

Production & Manufacturing

[edit]

The company is headquartered in Mainz and operates in 16 locations across 14 countries.[22]

Europe

[edit]

North America

[edit]

South America

[edit]

Asia

[edit]

Products

[edit]

Schott Pharma develops and manufactures drug containment solutions and delivery systems for injectable drugs, which it supplies to companies in the biotechnology and pharmaceutical industries.[31]

Its business is divided into two divisions:

  • Drug Containment Solutions: pharmaceutical vials, cartridges, and glass ampoules[32]
  • Drug Delivery Systems: prefillable glass syringes and syringes made from Cyclic olefin copolymers (COC), suitable for deep-cold medications.[33]
  • Prefillable glass syringe
    Prefillable glass syringe
  • Prefillable polymer syringe
    Prefillable polymer syringe
  • Ampoule
    Ampoule
  • Vial
    Vial
  • Cartridge
    Cartridge

Governance

[edit]

Schott Pharma is a subsidiary of SCHOTT AG, which holds controlling shares (as of 2023: 77%).[19][17] SCHOTT AG is owned by the Carl Zeiss Foundation.[25]

Schott Pharma is listed on the Frankfurt Stock Exchange's MDAX.[21]

Independent Supervisory Board

[edit]

In 2023 SCHOTT AG appointed a Supervisory Board for the subsidiary Schott Parma AG as follows:[34][35]

  • Peter Goldschmidt, (Chairman)
  • Dr. Wolfgang Wienand (Chairman of the Executive Board of Siegfried Holding AG)
  • Eva Kienle (CFO of KWS Saat SE & Co. KGaA)
  • Ann-Kristin Erkens (Corporate Senior Vice President, Financial and Business Controlling at Henkel Adhesive Technologies)
  • Christine Wening (employee stakeholder)
  • Mario Just (employee stakeholder)

Financial Results

[edit]
2022/23 2023/24
Turnover
Net Profit

References

[edit]
  1. ^ a b SCHOTT Pharma Annual Report 2022/2023 (accessed February 08, 2024)
  2. ^ Kansteiner, Fraiser (2023-12-23). "Glass specialist Schott Pharma touts 2023 sales growth, Serbia expansion and hiring plans". Fierce Pharma. Retrieved 2024-04-08.
  3. ^ "EQS-News: SCHOTT Pharma bestätigt Prognose für das Geschäftsjahr 2024 anlässlich seiner Q2-Ergebnisse; Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst" [EQS-News: SCHOTT Pharma confirms forecast for the 2024 financial year on the occasion of its Q2 results; financial year 2025 influenced by lower growth in syringes]. 4Investors.de (in German). 2024-05-14. Retrieved 2024-06-24.
  4. ^ Rauffmann, Theresa (2024-06-27). "Abhängigkeit vom Geschäft mit Diätspritzen wird zum Problem" [Dependence on the business with diet syringes becomes a problem]. www.handelsblatt.com. Retrieved 2024-09-18.
  5. ^ a b Ibrahim, Samir (2023-09-28). "Schott Pharma startet erfolgreich an der Frankfurter Börse". tagesschau.de (in German). Retrieved 2024-06-24.
  6. ^ a b c Nünchert, Ike (2022-08-03). "SCHOTT Pharma: Carve-Out für ein mögliches IPO" [SCHOTT Pharma: Carve-Out for a possible IPO]. Going Public. Retrieved 2024-06-24.
  7. ^ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
  8. ^ "Impfstoff-Ampullen – Rohrglas für Lebensretter - VBG Spezial". glaskeramik.org. VBG. 2021-07-04. Retrieved 2024-02-28.
  9. ^ Dunleavy, Kevin (2023-09-06). "After one year as standalone business, glassmaker Schott Pharma sets course for IPO". Fierce Pharma. Retrieved 2024-06-24.
  10. ^ Kansteiner, Fraiser (2022-01-08). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-02-28.
  11. ^ Landsteiner, Fraiser (2022-08-01). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-06-24.
  12. ^ Wilkes, William; Gopinath, Swetha (2023-06-22). "Schott to Hold IPO of Medical Glassware Unit in September: Bloomberg.com". Bloomberg.com: N.PAG–N.PAG.
  13. ^ a b "Schott Pharma trades up following biggest German IPO since Porsche: Global Capital". Global Capital: N.PAG–N.PAG. 2023-10-16.
  14. ^ Gopinath, Swetha (2023-09-28). "Germany's Schott Raises €813 Million in IPO of Medical-Glass Arm". www.bloomberg.com. Retrieved 2024-06-24.
  15. ^ gsp (2023-09-29). "Schott Pharma geht mit Freshfields an die Frankfurter Börse" [Schott Pharma goes to the Frankfurt Stock Exchange with Freshfields]. Extrajournal.Net (in German). Retrieved 2024-06-24.
  16. ^ "Schott Pharma prices IPO at 27 euros per share". Reuters. 2023-09-27. Retrieved 2024-06-24.
  17. ^ a b "SCHOTT Pharma feiert erfolgreiches Börsendebüt: Erstkurs über Ausgabepreis" [SCHOTT Pharma celebrates successful stock market debut: First price on issue price]. Finanzen Net (in German). 2023-09-28. Retrieved 2024-06-24.
  18. ^ Farr, Emma-Victoria; Mayo Cerqueiro, Pablo (2023-09-28). "Schott Pharma shares jump 16% in Frankfurt trading debut". reuters.com. Reuters. Retrieved 2024-02-28.
  19. ^ a b "Schott Pharma startet erfolgreich an der Börse". tagesschau.de. 2023-09-28. Retrieved 2024-02-28.
  20. ^ Ingerl, Christian (2023-12-13). "Profitabler Small Cap: Zulieferer Schott Pharma bald im SDax". Capital. Retrieved 2024-02-28.
  21. ^ a b Ruhkamp, Christoph (2024-10-04). "Finanzchefin bringt Schott Pharma in den MDax" [Chief Financial Officer brings Schott Pharma into the MDax]. boersen-zeitung.de (in German). Retrieved 2024-11-04.
  22. ^ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
  23. ^ Zeitung, Badische (2022-12-02). "SCHOTT Pharma: Ein globales Kompetenzzentrum in Müllheim". Badische Zeitung (in German). Retrieved 2024-06-24.
  24. ^ Schlegel, Marion (2023-12-19). "SDAX-Neuling Schott Pharma gibt ordentlich Gas: Zahlen kommen gut an". www.deraktionaer.de (in German). Retrieved 2024-06-24.
  25. ^ a b c "SCHOTT Pharma baut Produktion in China und Ungarn aus – ZWP online – das Nachrichtenportal für die Dentalbranche". www.zwp-online.info (in German). 2022-09-22. Retrieved 2024-06-24.
  26. ^ a b "SCHOTT: solides Ergebnis trotz konjunktureller Herausforderungen – ZWP online – das Nachrichtenportal für die Dentalbranche" [SCHOTT: solid result despite economic challenges]. www.zwp-online.info (in German). 2024-02-12. Retrieved 2024-06-24.
  27. ^ a b Herpai, Gergely (2024-07-12). "Schott Pharma's HUF 28 bln Investment Boosts Hungarian Pharmaceutical Manufacturing: Budapest Business Journal". Budapest Business Journal. 32 (14): 8–8.
  28. ^ "Schott Pharma Begins Construction on Serbia Plant: American Ceramic Society Bulletin". American Ceramic Society Bulletin. 103 (5): 49–49. July 2024.
  29. ^ a b Schott (2024-03-18). "SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina: Business Wire (English)". Business Wire (English).
  30. ^ Anselmo, Joelle (2024-03-27). "Schott Pharma to build $371M syringe factory: Construction Dive". Construction Dive: N.PAG–N.PAG.
  31. ^ SCHOTT Pharma Annual Report 2022/2023, SCHOTT Pharma, p. 14, retrieved 2024-02-28
  32. ^ Kaiser, Lea (2023-10-24). "Next generation pharma glass: SCHOTT AG launches FIOLAX® Pro Glass tubing". BusinessWire. Retrieved 2024-06-24.
  33. ^ "Schott Pharma rolls out pre-filled polymer syringes for deep-cold medication". NS Medical Devices. 2023-05-18. Retrieved 2024-02-28.
  34. ^ Mills, Jess (2023-05-02). "Schott appoints Supervisory Board of Schott Pharma". Glass International. Retrieved 2024-06-24.
  35. ^ "SCHOTT bestellt Aufsichtsrat der SCHOTT Pharma AG" [SCHOTT appoints Supervisory Board of SCHOTT Pharma AG]. ZWP-online. 2023-05-02. Retrieved 2024-06-24.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Schott_Pharma&oldid=1258686092"